ABCG2 and neoplasm: To our knowledge, this was the largest study to date involving real-life patients with a variety of actionable mutations treated with ABCP combination therapy, and the only one to report specific chemo-immunotherapy outcomes in patients with CNS metastases from EGFR-mutated or ALK-positive tumours after TKI exhaustion.